Foundation Adds New Markers To FoundationOne Cancer Testing Platform
Executive Summary
US FDA and the Centers for Medicare and Medicaid Services have already accepted FoundationOne for Parallel Review and Expedited Access for breakthrough devices. The new markers will help identify patients best-suited to immunotherapy or other targeted therarapies, the company says.